• about us | Enterprise Therapeutics | Treatment of respiratory diseases

LEADERSHIP TEAM

Dr John Ford

Dr John Ford

Chief Executive Officer

Dr John Ford has more than 18 years of ion channel, drug discovery and development experience. More...

Prof Martin Gosling

Prof Martin Gosling

Chief Scientific Officer

Prof Martin Gosling has spent his research career exploiting the therapeutic potential of ion channels in both industrial and academic settings. More...

Charles Johnson, MD

Charles Johnson, MD

Interim Chief Medical Officer

Dr Johnson, was named interim CMO of Enterprise Therapeutics in October of 2018. More...

Dr Henry Danahay

Dr Henry Danahay

Head of Biology

Dr Henry Danahay gained a BPharm and PhD from the Welsh School of Pharmacy before joining the Novartis Respiratory Diseases Group. More...

Dr Stephen Collingwood

Dr Stephen Collingwood

Head of Chemistry

Dr Steve Collingwood obtained his first degree in chemistry from the University of Durham and his PhD in organic chemistry from the University of Newcastle. More...

Dr Phil Boyd

Dr Phil Boyd

Chief Financial Officer

Dr Phil Boyd was CFO of Syntaxin Ltd from 2007 through to the acquisition by Ipsen in July 2013, and CFO of Tiziana Lifesciences plc (AIM: TILS) from 2014 to 2015. More...

Paul Russell

Paul Russell

Project Director (Development)

Paul has more than 20 years’ experience in the pharma and biotech industry. More...

Enterprise is a biopharmaceutical company dedicated to the research and development of novel therapies for the treatment of respiratory diseases of high unmet medical need and commercial opportunity – the company plans to initiate clinical trials in 2019.

Scientific Strategy

Enterprise is developing muco-regulatory drugs that are expected to help respiratory patients by improving their ability to breath and reduce the number of lung infections they experience leading to a longer and more healthy life.

Learn more

Pipeline

Enterprise has developed a pipeline of novel low molecular weight compounds with first in class potential – our most advanced compounds, which target ion channels in the airway epithelium are expected to enter human trials in late 2019.

Learn more